The anatomical drawing lessons from this Thai teacher are breathtaking – The Courier

Drawing a human body is not the easiest thing, and it takes years of practice to get a correct result. There are so many shapes, proportions, muscles, and bones in our bodies that it takes an incredible knowledge of human anatomy to depict them on paper. But there is Wannarit Karin, who is a hit with these breathtaking anatomical drawing lessons.

Wannarit Karin is a Thai artist who founded the ART of Anatomy Academy. The latter has mastered the techniques of anatomical drawing so well that he decided to pass on his knowledge to art students.

In her drawings, Karin highlights the most complex parts of the human body with incredible precision, from tendons and joints to muscle tissue.

Wannarit Karin teaches two courses: the first aims to give students an in-depth knowledge of anatomy and to untangle the parts that are most difficult to depict. The second is titled Drawing the Head and consists of practicing drawing a human face from a doll. Again, you need a good knowledge of the structure of the face, taking into account light and shadow.

In Wannarit Karins classes, art meets medicine.

As a reminder: Thanks to the knowledge of human anatomy and anatomical drawing, many artists were able to excel in classical painting. In addition, the greatest painters in history such as Da Vinci, Michelangelo or even Rembrandt have examined the human body and even participated in dissections to perfect their art!

Follow this link:
The anatomical drawing lessons from this Thai teacher are breathtaking - The Courier

‘Run’ | Anatomy of a Scene – The New York Times

Hi, Im Aneesh Chaganty, and Im the co-writer and director of Run. O.K. So the scene thats playing out right now takes place in the second act of the movie. Without giving much away, the basic setup is this. So our daughter, played by newcomer Kiera Allen, has been locked in her room by her misaligned mother, played by veteran Sarah Paulson, and is convinced that she needs to escape. From a form standpoint, I think what youre about to watch is actually one of the few sequences that breaks the pattern of the films aesthetic. Much of the films style is sort of borrowed from the films of Hitchcock and Shyamalan, and those films dont just choose shots because one thing can happen in them. They designed frames where, like, four or five things can happen in them. So to borrow a page out of their book, I storyboarded every single frame of this movie by hand before we started shooting. You can actually compare the boards to the final film. Its all pretty identical. So right now, were watching Chloe, whos this super resourceful and smart and inventive girl, sort of MacGyver a solution out of her room. Chloe uses a wheelchair, so a solution that an able-bodied person might have come up with wont work for her. She has to overcome that with just sort of pure intelligence, and she does. Every single shot inside this room here is repeated from an earlier shot in the movie. I wanted to be super spare with the visuals of this movie and always design frames that could be repeated so that when things start to explode narratively, like right now, it would feel like real catharsis. [MUSIC PLAYING] So all of this was shot on a stage in Winnipeg. We basically created the entire second story of his house on a stage, and the first story and the outside what youre looking at now is all on-location. So now were kind of jumping into the single most complex shooting process of the entire film, where this whole sequence is about to stitch so many different skill sets and elements and shooting days into one. So she just kind of comes out onto her roof. Were landing on a shot of Kiera in a stage on a set where the roof is actually flat and the walls are tilted to the side. It looks sort of like a really cool its hard to describe, but just movie magic makes that work. So the cameras just tilted. Shes actually perfectly flat on the ground. Were just tilting her hair a little bit and occasionally blowing wind to the side. And thats her face pushing forward a little bit, and sort of a blue screen behind her. The next shot youre going to see is going to be from the side, and that is a stunt double. But it looks like Kiera because we face-replaced Kieras face onto it. And this shot sort of was actually the first shot that we did on day one of shooting. And we had to shoot it on day one, because we shot in Winnipeg, Canada, which is, like, the coldest place ever, and we had to shoot out our exteriors first before everything started snowing. We started shooting October 31st of 2018. By the way, the house was chosen because it just felt like when we saw it that it looked like it was, like you could put it on a movie poster and draw it out and put Sarah Paulsons face above it, and it just had the vibes of this old-school, Hitchcock house, so theres just like secrets inside of it and stuff. This is a shot on set, again, on this little fake, made roof. This is another shot on set. Obviously, we did not put Kiera on an actual roof with danger. But this whole sequence, we shot over multiple, multiple days. And she still has a bunch of water in her mouth that she swallowed from earlier. She plugs in a soldering iron, heats up the soldering iron, and puts the soldering iron to this glass in the cold, where it immediately starts to kind of crack because the heat is expanding it, and then immediately will spit out some water onto the glass, where it shatters the rest of it. This is actually a technique. One of my best friends dads is a glass blower, and taught me this over the phone. So thats the end of one of the biggest set pieces of the movie, which honestly tries to do what we were trying to do with this whole movie, which is take a normal house and turn every single element of that house into a massive Burj Khalifa-scale obstacle.

Excerpt from:
'Run' | Anatomy of a Scene - The New York Times

ABC Sets 2021 Scripted Series Premiere Dates; ‘The Rookie’ & ‘Call Your Mother’ Join Schedule, ‘Grey’s’-Led Thursday Returns In March, ‘Black-ish’…

ABC has firmed up its midseason schedule, setting up early 2021 premiere dates for its scripted series. That includes ABCs returning scripted series and new comedy Call Your Mother, starring Kyra Sedgwick.

Call Your Mother and The Rookie, which were originally on ABCs fall schedule before being pushed, are slated in their previously designated slots, Wednesday 9:30 PM behind The Conners, and Sunday at 10 PM, respectively.

As ABC Entertainment president Karey Burke indicated in May, Black-ish, joined by spinoff Mixed-ish, will be back in the Tuesday 9-10 PM hour starting in January. The Tuesday 8-10 PM block was temporary taken over by The Bachelorette this fall as the summer staples season was delayed by the pandemic. Black-ish, originally left on the bench for midseason, was subsequently summoned back for a fall run on Wednesdays.

On Tuesday, Black-ish and Mixed-ish will follow To Tell the Truth; The Rookie, whose return was delayed because of a later production restart, will again follow American Idol.

ABCs third new scripted series, drama Rebel, headlined by Katey Sagal, was only picked up in September, so it will be scheduled later. It comes from Greys Anatomy and Station 19 showrunner Krista Vernoff.

The two Vernoff-run series, along with Thursday companion A Million Little Things, will be back after a winter break on March 3. This is the latest ever that Greys has kicked off its midseason run, but the ongoing pandemic has been forcing a lot of scheduling changes. The rest of ABCs scripted series will resume airing originals in January, including The Good Doctor, airing behind The Bachelor.

Serving as a bridge on Thursday while the scripted lineup is resting are reality series Celebrity Wheel of Fortune, The Chase and The Hustler.

Here are ABCs early 2021 scripted premiere dates. New shows are in bold.

SUNDAY, JANUARY 310-11 PM The Rookie (season premiere)

MONDAY, JANUARY 1110-11 PM The Good Doctor

WEDNESDAY, JANUARY 138-8:30 PM The Goldbergs8:30-9 PM American Housewife9-9:30 PM The Conners9:30-10 PM Call Your Mother (series premiere)

WEDNESDAY, JANUARY 2010-11 PM For Life

TUESDAY, JANUARY 269-9:30 PM Black-ish (new day and time)9:30-10 PM Mixed-ish (season premiere)10-11 PM Big Sky

THURSDAY, MARCH 48-9 PM Station 199-10 PM Greys Anatomy10-11 PM A Million Little Things

NEW SERIES DESCRIPTION

CALL YOUR MOTHER Jean, an empty-nester mom, wonders how she ended up alone while her children live their best lives thousands of miles away. She decides her place is with her family, and as she reinserts herself into their lives, her kids realize they might actually need her more than they thought.

Go here to see the original:
ABC Sets 2021 Scripted Series Premiere Dates; 'The Rookie' & 'Call Your Mother' Join Schedule, 'Grey's'-Led Thursday Returns In March, 'Black-ish'...

Debbie Allen Reveals the Real Reason Why ‘Grey’s Anatomy’ Has Been Such a Success – Parade

Dance Dreams: Hot Chocolate Nutcracker (Nov. 27 on Netflix) provides a fascinating behind-the-scenes look at the life and career of Greys Anatomy star and Emmy-winning choreographer Debbie Allen, 70. The documentary shines a spotlight on the Debbie Allen Dance Academy (DADA) as she prepares young dancers for her reimagined holiday production of The Nutcracker.

Why produce your own version of The Nutcracker?

I looked at the origins of The Nutcracker in the U.S. and [how choreographer] George Balanchine was trying to keep the New York City Ballet alive. So I decided to do my version and make it fun and funny.

What do students at your dance academy learn other than dance?

My own sense of discipline, completion, ability to take criticism and go the distance come out of my dance training. They are a byproduct of studying the performing arts. The creative instinct is nurtured, discipline is nurtured by learning to be part of a groupbecause if you do a great leap, someone has to catch you.

Related: Debbie Allen Will Teach You to Dance During the Coronavirus Pandemic

Youre an executive producer, star and director on Greys Anatomy. Why has that show endured?

Its about real people and real relationships. It happens to be in a hospital, which has inspired millions of young people to go into the medical profession, especially women. But at the end of the day, its about falling in love, falling out of love, betrayals, competitions. The people on our show ring so true.

Did you have big dreams as a child?

I spent a lot of time in my backyard in Houston looking up at the stars. Contemplating the universe when I was a little girl, I always saw myself in it, so that was always a big picture. Always.

What inspired you to reinvent The Nutcracker with rats instead of the Mouse King?

Everybody grows up with The Nutcracker. It was something that I dreamed about when I was a little kid and there were no productions that had Black kids in Houston. I remember doing Welcome to Flowerland as part of a church thing, and I participated in a lot of different Nutcrackers.

One day I took my son Thumpety [Norm Nixon Jr.], my niece Condola Rashad and my daughter, Vivian, to The Nutcracker downtown. And right in the middle of the show, Thumpety, my son, was just bored to death. He was just like, Uugghh. He couldnt have been more than about 4 or 5 years old, and he screamed out loud right in the middle of the Dorothy Chandler Pavilion, When is the rat coming?! And the audience howled. Oh, my God, they laughed. I was so embarrassed, but it was so cute. And I realized they wanted to see a rat; he didnt want to see the Mouse King.

This is a family affair. Your husband and daughter are involved, and your son was the inspiration. Was it hard to rope them in?

It has its challenges because everybody has their own ideas. Theyve grown up with me. Theyve been on the plane when I went to London to do Carrie. Theyve been with me everywhere Ive gone, including when I went to China as cultural ambassador [of dance] for the United States. They have always been a part of my life.

Youre going to be remembered for your roles, your directing and producing, and choreography, but Hot Chocolate Nutcracker will introduce people to this other side of you, which is opening doors for people of color in the dance world. Youll be remembered also by the children whose lives that you touch.

I call them my DADA diaspora, because now were 20 years old and they are everywhere. My kids are everywhere and doing such wonderful things. Improving the quality of life for people in their community, sharing their gifts, inspiring other young people to do what they have done through their learning, creating nonprofits.

DADA provides life lessons every day. It trains them to be ready to get out in the world, be adults, and be the ones that create opportunity or make decisions. Everything that were teaching is really developing their humanity.

On Nov. 14 we celebrated our 20th anniversary in the parking lot of the Rose Bowl, and the real focus of this celebration was those kids, who they are, where they are, and what theyre doing. I cant even do them all, theres so many of them. Theyre in some of the best universities, full-scholarship students, dancing with great companies, in television series, creating nonprofits, doing programming to help women who are battered and abused. Theyre doing all of these wonderful things.

It feels like I have birthed another nation, if you will, another generation along with my own kids. And thats something that I take very seriously, and Im still doing it every day.

Related: How to Vote for Your Favorite Couple on Dancing With the Stars

In the time of coronavirus, obviously, you wont be doing a production this year, which is your big fundraiser to provide scholarships for some of your DADA students. So how will you keep going?

Well, first of all, we responded to this metamorphosis, if you will, this evolution of the virtual world. So many dance schools have closed, so many performing arts centers are closed, and we know the theaters are dark and the concert world. Film and television are just now getting back up to producing, and a lot of those productions have also shut down again when they didnt have the right COVID protocols.

So I was adamant that, OK, weve got to shut the doors, but were not shutting down. I started teaching my live Instagram class and I just did it as a gift. And then I realized thousands of people were taking the class, so I did it every week. Ive been doing it since March every Wednesday at one oclock. And Saturday I started a class for the younger ones because its turned into a whole other thing.

But how do we survive this as the academy? The fundraiser, the drive-in gala at the Rose Bowl parking lot, was a big deal for us with people at a drive-in in their cars having a live experience with people they quarantine with, so its safe. But we are indebted to the foundations and people that support us.

Wallis Annenberg and the Annenberg Foundation have supported DADA for I would say the better part of almost 20 years, and the Berry Gordy Family Foundation, and the David Kobrin Foundation. Recently, were getting grants because were in the middle of a capital campaign. This couldnt be a worse time to be trying to build a building, but were moving forward. We have to. We have to because we know the doors are going to open and were going to be ready to take the kids back in.

People see what we do. They see that its all going to the kids. Its all going to what its supposed to be. For 20 years, we had a really great record of what we do, and right now the kids need it more than ever. Can you imagine how exhausted they are from Zoom classes and virtual everything? So when we have a Zoom class and its live, thats something. And we have very small classes at the studio. We used to have a studio with 30 to 40 kids, we cant do that anymore. Some classes are four, five kids.

Between DADA and Greys, your dance card is pretty full, but last season you guest starred as Shemar Moores mother on S.W.A.T. Any chance that youll be back this season?

They shoot on Saturdays, actually, so Im waiting to get that call from Shemar. Debbie, come on. I need you to come back. And when he calls, Ill try to figure it out. Everybodys under such strict protocols and testing. Any show thats really working is kind of OK. But I had a good time being his mom. He is such a lovely man in real life and has such a big heart about the world, and is so wanting his show to reflect what is happening in the world right now.

Who do you credit for the success story that is your life and the barriers you have broken?

I have to credit my mother, Vivian Ayers Allen, because she raised usme, Phylicia [Rashad], Tex and my baby brother, Huey, who came much later. She really instilled in us a sense that we are children of the universe and that there were no borders and no boundaries in the real world. W
e got a sense of that when she took us to Mexico. It was the first time we could go to a lunch counter and have lunch because it wasnt segregated.

My mother instilled in us a sense of space, and creativity, and productivity, and that we were born to go and do something. Its no surprise Phylicias as successful as she is, and me, and my brother Tex, and my brother Hueys a successful banker. Thank God somebody can write a check.

Next, Greys Anatomy Is BackHeres What You Need to Know About Season 17

Celebrity interviews, recipes and health tips delivered to yourinbox.

Read the rest here:
Debbie Allen Reveals the Real Reason Why 'Grey's Anatomy' Has Been Such a Success - Parade

‘Grey’s Anatomy’: Does the Cast Get Along With Katherine Heigl Now? – Showbiz Cheat Sheet

Greys Anatomy has seen a lot of characters come and go. Some of the actors and actresses like Sandrah Oh, who played Cristina Yang, are lucky enough to leave on their own accord. While some, like Katherine Heigl, leave under much murkier circumstances. Heigls exit shook fans of the show and she became infamous for being hard to work with. But has the cast of the show forgiven Heigl for her behavior?

Drama with Heigl, who played Isobel Stevens, started when she pulled herself out of the running for an Emmy nomination for her work on Greys.

I did not feel that I was given the material this season to warrant an Emmy nomination and in an effort to maintain the integrity of the academy organization, I withdrew my name from contention, she said in a statement. In addition, I did not want to potentially take away an opportunity from an actress who was given such materials.

She made her final appearance on the show in Jan. 2010, during the shows sixth season.

At the time of the drama, Heigls character had become a focal point in the series. Izzie Stevens relationship with Alex Karev was one of the main romances on the show so when Heigl left, the writers had to figure out what to do with Karev.

RELATED:5 Greys Anatomy Episodes That Changed the Shondaland Series Forever

When word comes down that an actor is leaving the show, and what youve got scripted is a wedding, showrunner Krista Vernofftold Variety.

Katies departure changed the course of the Alex-Izzie love story quite abruptly. One of the things about working in television and being a TV writer is you have to be able to pivot. You dont have to love pivoting, but youd better be willing to throw everything out and work through the night on a completely different story at the 11th hour.

Heigl famously feuded with Isaiah Washington, who played Dr. Preston Burke, after she claimed that he had made a homophobic remark toward their co-star T.R. Knight.

When Washington addressed the situation, Heigl famously said that he needed to just not speak in public.

According to Entertainment Tonight, after the incident, Washington wrote an apology and shot a PSA for GLAAD.

Washington recently came for Heigl by tweeting a photo of her, stating This woman once proclaimed that I should never be allowed to speak publicly again. The world agreed with her proclamation back then and protested for my job and my head in 65 languages. I wish I was on Twitter in 2007, because I will NEVER stop exercising my free speech.

So, it doesnt seem as if Washington has let the feud go.

In 2014, show creator Shonda Rhimes also threw a little shade at Heigl while discussing the fact that she would not be allowing any drama to take place on the set ofScandal.

There are no Heigls in this situation, she toldThe Hollywood Reporter of the Scandal cast. I dont put up with bullsh** or nasty people. I dont have time for it.

See the rest here:
'Grey's Anatomy': Does the Cast Get Along With Katherine Heigl Now? - Showbiz Cheat Sheet

Nordic Nanovector ASA: Results for the Third Quarter 2020 – BioSpace

OSLO, Norway, Nov. 19, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's management team will take place today in Oslo at 08.30 CET, see details below. A link to the webcast and the presentation is available from the company's homepage (www.nordicnanovector.com).

Lars Nieba, Interim CEO of Nordic Nanovector, said: "Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. Generating these data will require us to successfully navigate the latest challenges of increased COVID-19 restrictions. We remain confident in our ability to achieve this goal, aided by the protocol amendments, the possibility to reduce the patient sample, and all the other measures we are actively implementing to drive patient recruitment into PARADIGME."

Q3'2020 Highlights

Events after Q3'2020

Financial Highlights

(Figures in brackets = same period 2019 unless otherwise stated)

Outlook

The company continues to target the readout of three-month top line data from PARADIGME in H2'2021. Approval of protocol amendments is proceeding as planned and completed in the best-recruiting countries, and other initiatives to increase the rate of enrolment are underway. The company also targets the readout of three-month top line data from the second cohort of the Archer-1 trial in H1'2021.

However, the impact of the COVID-19 pandemic on patient recruitment has worsened in light of the emergence of a second wave resulting in severe travel restrictions being implemented in the various countries where we are executing our clinical studies. These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. Several proactive actions have been taken to minimize the impact of these travel restrictions which could blunt further delays in completing enrolment and delivering preliminary results as targeted.

The company has taken steps to conserve cash and following the recent successful private placement, Nordic Nanovector has a cash runway that extends into Q3'2021.

Despite the challenging times, the many positive actions the company has made in the last nine months have improved the prospects of delivering pivotal results from PARADIGME in H2'2021.

The company continues to believe that, if positive, these trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin as a highly promising new targeted therapy that can address the unmet needs of R/R FL patients.

Presentation and live webcast Q3 2020 results

A presentation and live webcast by Nordic Nanovector's management team will take place today at 8:30 am CET.

The webcast can be accessed from http://www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation is available at http://www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)

Tel: +44 203 926 8535

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Further information can be found at http://www.nordicnanovector.com .

Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--results-for-the-third-quarter-2020,c3239830

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-results-for-the-third-quarter-2020-301176750.html

SOURCE Nordic Nanovector

Company Codes: Bloomberg:NANO@NO, ISIN:NO0010597883, Oslo:NANO, RICS:NANO.OL

Visit link:
Nordic Nanovector ASA: Results for the Third Quarter 2020 - BioSpace

Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) – TechnoWeekly

The global Healthcare Nanotechnology (Nanomedicine) Market study offers a compilation of the current, historical, and future outlook of the industry as well as the factors responsible for market growth. With a SWOT analysis, the business study highlights the weaknesses, strengths, opportunities, and threats of each Healthcare Nanotechnology (Nanomedicine) Market player in a comprehensive way.

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-64780?utm_source=SA/technoweekly

Under the COVID-19 outbreak analysis, this report provides analysis of import, supply chain, and export to future influence on the industry and regional government policies. Enterprise competition pattern, detailed analysis about market status, advantages and disadvantages of enterprise products, macroeconomic policies and regional industrial layout characteristics, industry development trends have also been included. The trends of product sales channel will be offered as well.

Considering COVID-19, this report offers a complete and exhaustive analysis on how the epidemic has pushed transformation and reform in the industry. The market study can help understand the market expansion and strategies for business accordingly. In the strategy analysis, it gives insights from market positioning marketing channel to potential growth strategies, thereby providing an in-depth analysis for new entrants or existing competitors in the Healthcare Nanotechnology (Nanomedicine) industry.

Key Players: Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd..

The market analysis on the Healthcare Nanotechnology (Nanomedicine) offers a birds eye view of the current proceeding within the Healthcare Nanotechnology (Nanomedicine) Market. The market analysis report has incorporated an analysis of various factors that augment the markets growth. It constitutes restraints, trends, and drivers that transform the market in either a negative orpositive manner.

Healthcare Nanotechnology (Nanomedicine) Market

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-64780?utm_source=SA/technoweekly

This market analysis also offers the scope of different segments and applications that can actually impact the market in the future. The thorough information is based on present trends and historic milestones. The market analysis mentions the volume of sales by region from 2015 to 2026. A thorough evaluation of the limitations included in the market analysis portrays the drivers and gives room for strategic planning.

Global Healthcare Nanotechnology (Nanomedicine) Market: Segment Analysis

Each type offers information about return sover the forecast period of 2018 to 2028. The sales method segment also offers revenue by volume and sales over the forecast period of 2018 to 2028. Understanding the segments helps in classifying the importance of various factors that support market growth.

Following are the segmentation covered by the market study: By Application (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), By Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases and Other Diseases)

Global Healthcare Nanotechnology (Nanomedicine) Market: Regional Analysis

The market analysis report includes a thorough study of various factors that determine regional growth such as environmental, economic, social political status, technology, and region. Market analysis has studied the data of sales, revenue, and manufacturers of each region. The market analysis provides region-wise volume and revenue for the forecast period of 2016 to 2028. This market analysis will support the market participants to understand the potential worth of investment in a particular region.

Region- wise Analysis of the Global Healthcare Nanotechnology (Nanomedicine) Market covers: North America Europe Asia Pacific Middle East and Africa South America

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-64780?utm_source=SA/AF

Global Healthcare Nanotechnology (Nanomedicine) Market: Competitive Landscape

This market analysis report classifies numerous key manufacturers of the industry. It supports the reader in understanding the policies and collaborations that the industry participants are focusing on in order to combat competition in the industry. The comprehensive market analysis offers a note worthy microscopic look at the industry. The market analysis can classify the footprints of the manufacturers by giving the global revenue of manufacturers and sales by manufacturers, and the global price of manufacturers over the forecast period of 2018 to 2028.

Major Aspects covered in the Report are

Further, the report provides niche insights for a decision about every possible segment, helping in the strategic decision-making process and market size estimation of the Healthcare Nanotechnology (Nanomedicine) Market on a regional and global basis. Unique research designed for market size estimation and forecast is used for the identification of major companies operating in the market with related developments. The report has an exhaustive scope to cover all the possible segments, helping every stakeholder in the Healthcare Nanotechnology (Nanomedicine) Market.

Reasons for buying this report:

Why Do Companies Trust QMI?

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Excerpt from:
Healthcare Nanotechnology (Nanomedicine) Market is Slated To Grow Rapidly In The Coming Years (2020 2028) - TechnoWeekly

NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States – Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN : FR0011341205 the Company), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the SEC) relating to a proposed initial public offering of its American Depositary Shares (ADSs), representing ordinary shares, in the United States (the U.S. Offering), and a concurrent private placement of its ordinary shares in Europe (including France) and other countries outside of the United States (the European Private Placement, and together with the U.S. Offering, the Global Offering). All securities to be sold in the Global Offering will be offered by the Company. The number of ordinary shares to be represented by each ADS, the number of ADSs and ordinary shares to be offered and the price range for the proposed Global Offering have not yet been determined. The Company has applied to list its ADSs on the Nasdaq Global Market under the ticker symbol NBTX. The Companys ordinary shares are listed on Euronext Paris under the symbol NANO.

Jefferies LLC is acting as global coordinator for the Global Offering, and Evercore Group, L.L.C. and UBS Securities LLC are also acting as joint book-running managers for the U.S. Offering. Gilbert Dupont is acting as manager for the European Private Placement.

The securities referred to in this press release will be offered only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at 888-474-0200, or by email at ecm.prospectus@evercore.com; or from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, or by telephone at 888-827-7275, or by email at ol-prospectusrequest@ubs.com.

A registration statement relating to the securities referred to herein has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The registration statement can be accessed by the public on the website of the SEC.

About NANOBIOTIX

Nanobiotix is a French, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. Nanobiotixs novel, proprietary lead technology, NBTXR3, is being evaluated in locally-advanced head and neck squamous cell carcinoma (HNSCC) of the oral cavity or oropharynx in elderly patients unable to receive chemotherapy or cetuximab with limited therapeutic options. Nanobiotix is also running an Immuno-Oncology development program. The Companys headquarters are in Paris, France, with a U.S. affiliate in Cambridge, Massachusetts, and European affiliates in France, Spain and Germany.

Read more here:
NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States - Business Wire

Latest Innovative Report on Oral Contrast Agent Market | Research Report Explores The Trade Trends For The Forecast 2020 2026 – The Daily…

Global Oral Contrast Agent Market research report is in-depth study on the market size, growth, trends, market share, as well as detailed industry analysis. The research report offers the study of market size of the Oral Contrast Agent Market in terms of value of the year 2020 and estimated market size of 2026. The study offers the analysis of market performance for the forecast period 2015-2026, accounting on the basis of various growth determinants over the last five years.

Request Free Sample Report athttps://reportocean.com/industry-verticals/sample-request?report_id=QY809

The key players profiled in the research study of Oral Contrast Agent Market include:The major vendors covered:GE Healthcare (US)Bracco Imaging (Italy)Bayer HealthCare (Germany)Guerbet (France)Lantheus (US)Daiichi Sankyo (Japan)Unijules Life Sciences (India)J.B. Chemicals and Pharmaceuticals (India)Spago Nanomedicine (Sweden)Taejoon Pharm (South Korea)Jodas (India)Magnus Health (India)

The study on the global Oral Contrast Agent Market for all relevant companies dealing with the Oral Contrast Agent Market and related profiles include data in quantitative terms, product portfolio, and business strategy along with active tracking of recent developments. The research study is a wholesome collection of primary and secondary data collected and analysed from valuable information sources. The market forecast is based on data ranging from the year 2015 until 2026. For easy understanding, the study includes data representation in the form of various graphs and tables.

The main sources of gathering relevant data are industry experts from the Oral Contrast Agent Market industry, including processing organizations, management organizations and analytical services providers that actively contribute in the value chain of the Oral Contrast Agent Market. To compile the analytical study, we interviewed various sources and collected qualitative and quantitative information with key focus to determine future prospects of the Oral Contrast Agent Market. While, the secondary research studies include critical information about the industrial value chain, strategical developments by key companies and studying annual reports of the market players while tracking their key initiatives and contribution in market share.

The major objective of the Oral Contrast Agent Market study are:

To analyse Oral Contrast Agent Market status, key players, key market, growth opportunity and future forecast.

To offer the Oral Contrast Agent Market development in North America, Europe, China, Japan and Southeast Asia.

To strategically profile the companies dealing in Oral Contrast Agent Market and broadly study their strategic development plans to acquire key share in the global marketplace.

The research report provides data information and detailed profile analysis of leading companies of the Oral Contrast Agent Market.

Table of Content

1 Study Coverage1.1 Oral Contrast Agent Product Introduction1.2 Market Segments1.3 Key Oral Contrast Agent Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global Oral Contrast Agent Market Size Growth Rate by Type1.4.2 Barium-based Contrast Media1.4.3 Iodinated Contrast Media1.4.4 Gadolinium-based Contrast Media1.4.5 Microbubble Contrast Media1.5 Market by Application1.5.1 Global Oral Contrast Agent Market Size Growth Rate by Application1.5.2 Cardiovascular Disorders1.5.3 Cancer1.5.4 Gastrointestinal Disorders1.5.5 Musculoskeletal Disorders1.5.6 Neurological Disorders1.5.7 Nephrological Disorders1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Oral Contrast Agent Market Size, Estimates and Forecasts2.1.1 Global Oral Contrast Agent Revenue 2015-20262.1.2 Global Oral Contrast Agent Sales 2015-20262.2 Global Oral Contrast Agent, Market Size by Producing Regions: 2015 VS 2020 VS 20262.2.1 Global Oral Contrast Agent Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Oral Contrast Agent Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Oral Contrast Agent Competitor Landscape by Players3.1 Oral Contrast Agent Sales by Manufacturers3.1.1 Oral Contrast Agent Sales by Manufacturers (2015-2020)3.1.2 Oral Contrast Agent Sales Market Share by Manufacturers (2015-2020)3.2 Oral Contrast Agent Revenue by Manufacturers3.2.1 Oral Contrast Agent Revenue by Manufacturers (2015-2020)3.2.2 Oral Contrast Agent Revenue Share by Manufacturers (2015-2020)3.2.3 Global Oral Contrast Agent Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Oral Contrast Agent Revenue in 20193.2.5 Global Oral Contrast Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Oral Contrast Agent Price by Manufacturers3.4 Oral Contrast Agent Manufacturing Base Distribution, Product Types3.4.1 Oral Contrast Agent Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Oral Contrast Agent Product Type3.4.3 Date of International Manufacturers Enter into Oral Contrast Agent Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)4.1 Global Oral Contrast Agent Market Size by Type (2015-2020)4.1.1 Global Oral Contrast Agent Sales by Type (2015-2020)4.1.2 Global Oral Contrast Agent Revenue by Type (2015-2020)4.1.3 Oral Contrast Agent Average Selling Price (ASP) by Type (2015-2026)4.2 Global Oral Contrast Agent Market Size Forecast by Type (2021-2026)4.2.1 Global Oral Contrast Agent Sales Forecast by Type (2021-2026)4.2.2 Global Oral Contrast Agent Revenue Forecast by Type (2021-2026)4.2.3 Oral Contrast Agent Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Oral Contrast Agent Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)5.1 Global Oral Contrast Agent Market Size by Application (2015-2020)5.1.1 Global Oral Contrast Agent Sales by Application (2015-2020)5.1.2 Global Oral Contrast Agent Revenue by Application (2015-2020)5.1.3 Oral Contrast Agent Price by Application (2015-2020)5.2 Oral Contrast Agent Market Size Forecast by Application (2021-2026)5.2.1 Global Oral Contrast Agent Sales Forecast by Application (2021-2026)5.2.2 Global Oral Contrast Agent Revenue Forecast by Application (2021-2026)5.2.3 Global Oral Contrast Agent Price Forecast by Application (2021-2026)

6 North America6.1 North America Oral Contrast Agent by Country6.1.1 North America Oral Contrast Agent Sales by Country6.1.2 North America Oral Contrast Agent Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America Oral Contrast Agent Market Facts & Figures by Type6.3 North America Oral Contrast Agent Market Facts & Figures by Application

7 Europe7.1 Europe Oral Contrast Agent by Country7.1.1 Europe Oral Contrast Agent Sales by Country7.1.2 Europe Oral Contrast Agent Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe Oral Contrast Agent Market Facts & Figures by Type7.3 Europe Oral Contrast Agent Market Facts & Figures by Application

8 Asia Pacific8.1 Asia Pacific Oral Contrast Agent by Region8.1.1 Asia Pacific Oral Contrast Agent Sales by Region8.1.2 Asia Pacific Oral Contrast Agent Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific Oral Contrast Agent Market Facts & Figures by Type8.3 Asia Pacific Oral Contrast Agent Market Facts & Figures by Application

9 Latin America9.1 Latin America Oral Contrast Agent by Country9.1.1 Latin America Oral Contrast Agent Sales by Country9.1.2 Latin America Oral Contrast Agent Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America Oral Contrast Agent Market Facts & Figures by Type9.3 Central & South America Oral Contrast Agent Market Facts & Figures by Application

10 Middle East and Africa10.1 Middle East and Africa Oral Contrast Agent by Country10.1.1 Middle East and Africa Oral Contrast Agent Sales by Country10.1.2 Middle East and Africa Oral Contrast Agent Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 U.A.E10.2 Middle East and Africa Oral Contrast Agent Market Facts & Figures by Type10.3 Middle East and Africa Oral Contrast Agent Market Facts & Figures by Application

11 Company Profiles11.1 GE Healthcare (US)11.1.1 GE Healthcare (US) Corporation Information11.1.2 GE Healthcare (US) Description and Business Overview11.1.3 GE Healthcare (US) Sales, Revenue and Gross Margin (2015-2020)11.1.4 GE Healthcare (US) Oral Contrast Agent Products Offered11.1.5 GE Healthcare (US) Related Developments11.2 Bracco Imaging (Italy)11.2.1 Bracco Imaging (Italy) Corporation Information11.2.2 Bracco Imaging (Italy) Description and Business Overview11.2.3 Bracco Imaging (Italy) Sales, Revenue and Gross Margin (2015-2020)11.2.4 Bracco Imaging (Italy) Oral Contrast Agent Products Offered11.2.5 Bracco Imaging (Italy) Related Developments11.3 Bayer HealthCare (Germany)11.3.1 Bayer HealthCare (Germany) Corporation Information11.3.2 Bayer HealthCare (Germany) Description and Business Overview11.3.3 Bayer HealthCare (Germany) Sales, Revenue and Gross Margin (2015-2020)11.3.4 Bayer HealthCare (Germany) Oral Contrast Agent Products Offered11.3.5 Bayer HealthCare (Germany) Related Developments11.4 Guerbet (France)11.4.1 Guerbet (France) Corporation Information11.4.2 Guerbet (France) Description and Business Overview11.4.3 Guerbet (France) Sales, Revenue and Gross Margin (2015-2020)11.4.4 Guerbet (France) Oral Contrast Agent Products Offered11.4.5 Guerbet (France) Related Developments11.5 Lantheus (US)11.5.1 Lantheus (US) Corporation Information11.5.2 Lantheus (US) Description and Business Overview11.5.3 Lantheus (US) Sales, Revenue and Gross Margin (2015-2020)11.5.4 Lantheus (US) Oral Contrast Agent Products Offered11.5.5 Lantheus (US) Related Developments11.6 Daiichi Sankyo (Japan)11.6.1 Daiichi Sankyo (Japan) Corporation Information11.6.2 Daiichi Sankyo (Japan) Description and Business Overview11.6.3 Daiichi Sankyo (Japan) Sales, Revenue and Gross Margin (2015-2020)11.6.4 Daiichi Sankyo (Japan) Oral Contrast Agent Products Offered11.6.5 Daiichi Sankyo (Japan) Related Developments11.7 Unijules Life Sciences (India)11.7.1 Unijules Life Sciences (India) Corporation Information11.7.2 Unijules Life Sciences (India) Description and Business Overview11.7.3 Unijules Life Sciences (India) Sales, Revenue and Gross Margin (2015-2020)11.7.4 Unijules Life Sciences (India) Oral Contrast Agent Products Offered11.7.5 Unijules Life Sciences (India) Related Developments11.8 J.B. Chemicals and Pharmaceuticals (India)11.8.1 J.B. Chemicals and Pharmaceuticals (India) Corporation Information11.8.2 J.B. Chemicals and Pharmaceuticals (India) Description and Business Overview11.8.3 J.B. Chemicals and Pharmaceuticals (India) Sales, Revenue and Gross Margin (2015-2020)11.8.4 J.B. Chemicals and Pharmaceuticals (India) Oral Contrast Agent Products Offered11.8.5 J.B. Chemicals and Pharmaceuticals (India) Related Developments11.9 Spago Nanomedicine (Sweden)11.9.1 Spago Nanomedicine (Sweden) Corporation Information11.9.2 Spago Nanomedicine (Sweden) Description and Business Overview11.9.3 Spago Nanomedicine (Sweden) Sales, Revenue and Gross Margin (2015-2020)11.9.4 Spago Nanomedicine (Sweden) Oral Contrast Agent Products Offered11.9.5 Spago Nanomedicine (Sweden) Related Developments11.10 Taejoon Pharm (South Korea)11.10.1 Taejoon Pharm (South Korea) Corporation Information11.10.2 Taejoon Pharm (South Korea) Description and Business Overview11.10.3 Taejoon Pharm (South Korea) Sales, Revenue and Gross Margin (2015-2020)11.10.4 Taejoon Pharm (South Korea) Oral Contrast Agent Products Offered11.10.5 Taejoon Pharm (South Korea) Related Developments11.1 GE Healthcare (US)11.1.1 GE Healthcare (US) Corporation Information11.1.2 GE Healthcare (US) Description and Business Overview11.1.3 GE Healthcare (US) Sales, Revenue and Gross Margin (2015-2020)11.1.4 GE Healthcare (US) Oral Contrast Agent Products Offered11.1.5 GE Healthcare (US) Related Developments11.12 Magnus Health (India)11.12.1 Magnus Health (India) Corporation Information11.12.2 Magnus Health (India) Description and Business Overview11.12.3 Magnus Health (India) Sales, Revenue and Gross Margin (2015-2020)11.12.4 Magnus Health (India) Products Offered11.12.5 Magnus Health (India) Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)12.1 Oral Contrast Agent Market Estimates and Projections by Region12.1.1 Global Oral Contrast Agent Sales Forecast by Regions 2021-202612.1.2 Global Oral Contrast Agent Revenue Forecast by Regions 2021-202612.2 North America Oral Contrast Agent Market Size Forecast (2021-2026)12.2.1 North America: Oral Contrast Agent Sales Forecast (2021-2026)12.2.2 North America: Oral Contrast Agent Revenue Forecast (2021-2026)12.2.3 North America: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.3 Europe Oral Contrast Agent Market Size Forecast (2021-2026)12.3.1 Europe: Oral Contrast Agent Sales Forecast (2021-2026)12.3.2 Europe: Oral Contrast Agent Revenue Forecast (2021-2026)12.3.3 Europe: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Oral Contrast Agent Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Oral Contrast Agent Sales Forecast (2021-2026)12.4.2 Asia Pacific: Oral Contrast Agent Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Oral Contrast Agent Market Size Forecast by Region (2021-2026)12.5 Latin America Oral Contrast Agent Market Size Forecast (2021-2026)12.5.1 Latin America: Oral Contrast Agent Sales Forecast (2021-2026)12.5.2 Latin America: Oral Contrast Agent Revenue Forecast (2021-2026)12.5.3 Latin America: Oral Contrast Agent Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Oral Contrast Agent Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Oral Contrast Agent Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Oral Contrast Agent Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Oral Contrast Agent Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Oral Contrast Agent Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Oral Contrast Agent Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details16.3 Disclaimer

Inquire or Share Your Questions If Any before Purchasing This Report:https://reportocean.com/industry-verticals/sample-request?report_id=QY809

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Matthew SEmail:[emailprotected]

More:
Latest Innovative Report on Oral Contrast Agent Market | Research Report Explores The Trade Trends For The Forecast 2020 2026 - The Daily...

Integrative Medicine Therapies Effectively Increase Quality of Life for Patients With Myeloproliferative Neoplasms – Cancer Therapy Advisor

Patients with myeloproliferative neoplasms (MPNs) who were treated with certain integrative medicine (IM) therapies had lower levels of negative symptoms and reported a higher quality of life (QOL). These findings, from an online survey, were published in Cancer Medicine.

For this study, 858 patients with MPNs were recruited by researchers at the Mayo Clinic Arizona through social media and email during 2016. Patients were assessed by the MPN-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), Patient Health Questionnaire (PHQ)-2, Brief Fatigue Inventory (BFI) Usual, and for quality of life.

More than 2 dozen IM therapies were reported, including multiple forms of exercise, massage, nutrition, meditation, and several types of physical, group, and psychological therapies.

Lower average MPN-SAF TSS scores were reported by patients who participated in aerobic exercise (33.2 vs 39.7; P <.001) and strength training (34.0 vs 37.7; P =.013).

Mean QOL was reported as higher among patients who received massage (5.0 vs 4.6; P =.04) and went to support groups (5.4 vs 4.6; P =.002).

The likelihood of experiencing symptoms of depression was lower among patients who participated in aerobic exercise (odds ratio [OR], 0.60; 95% CI, 0.42-0.86; P =.006), yoga (OR, 0.61; 95% CI, 0.39-0.94; P =.025), and strength training (OR, 0.58; 95% CI, 0.37-0.91; P =.019).

This study may have been limited by its overwhelming gender bias, in which the ratio of women to men was 3:1.

The study authors concluded that in addition to pharmacologic therapies, IM therapies may aid in alleviating negative symptoms of MPN and increase quality of life.

Disclosure: Multiple authors declared affiliations with industry. Please refer to the original article for a full list of disclosures.

Reference

Gowin K, Langlais BT, Kosiorek HE, et al. The SIMM study: survey of integrative medicine in myeloproliferative neoplasms. Cancer Med. Published online November 3, 2020. doi:10.1002/cam4.3566

This article originally appeared on Oncology Nurse Advisor

See original here:
Integrative Medicine Therapies Effectively Increase Quality of Life for Patients With Myeloproliferative Neoplasms - Cancer Therapy Advisor

Learn from Leaders at Farfetch, Alibaba and, Rent the Runway at VOICES 2020 | BoF – The Business of Fashion

With just under two weeks to go, we are excited to share some of the latest confirmed speakers at VOICES, BoFs annual gathering for big thinkers.

Farfetch founder, chairman & chief executive Jos Neves joins Alibaba Group president J. Michael Evans in their first live conversation about the recent game-changing partnership with Richemont.

The renowned sleep expert Matt Walker joins Oura chief executive Harpreet Rai in a discussion about the science of sleep.

Rent the Runway co-founder & chief executive Jennifer Hyman will share her learnings on the pandemics impact on the fashion rental model.

Belgian economist Jan-Emmanuel De Neve will reveal insights on wellbeing, productivity, economic growth and inequality from The World Happiness Report.

Deepak Chopra, the New York Times best-selling author and pioneer of integrative medicine, and Carmen Busquets, investor and entrepreneur, will speak on how meditation can awaken the mind.

Rashad Robinson, president of Color of Change, a leading racial justice organisation driven by more than 7.2 million members who are building power for Black communities, will speak on the global racial reckoning of 2020.

Sinad Burke, activist and advocate for disability, will speak to Samira Nasr, editor-in-chief of Harpers Bazaar on inclusion in fashion and media.

Designer Jonathan Anderson and artist Anthea Hamilton will speak to BoFs Tim Blanks about their recent groundbreaking creative collaboration for Tate Britain.

Virgil Abloh, artistic director of Louis Vuitton Men will speak to Paul Davison, chief executive and co-founder of Clubhouse, the pioneering social audio app.

Discover the full agenda for VOICES 2020, where you can see an overview of each session and all the global experts we are convening for the fashion industrys most anticipated annual conference.

If youre a BoF Professional member, register here. If youre not, learn more and sign up for a 30-day trial to BoF Professional, which includes access to VOICES 2020.

For senior executives who want to go deeper, a VOICES 2020 Executive Pass will give you a more immersive VOICES experience.

VOICES 2020 is made possible in part through our partners McKinsey & Company, Affirm, SCAD and Invisible Collection.

BoFs ANNUAL GATHERING FOR BIG THINKERS

VOICES brings together the movers, shakers and trailblazers of the global fashion industry and unites them with the big thinkers, entrepreneurs and inspiring people who are shaping the wider world, hosted by BoF founder and editor-in-chief, Imran Amed, and led by BoF's expert editors and correspondents. Register now to reserve your spot.

1. THE WIDER WORLD: Making sense of 2020 and charting a way forward2. INSIDE THE FASHION SYSTEM: Addressing the industrys most important challenges and opportunities3. TECHNOLOGY & INNOVATION: Exploring how new technologies will change consumer behaviour4. REINVENTING RETAIL: Understanding how forces accelerated by the pandemic are completely reshaping the retail landscape5. LIVE YOUR BEST LIFE: Finding the balance, insight and inspiration to be the most authentic, healthy version of yourself

JOIN US FOR A GLOBAL CONVERSATION ABOUT THE FUTURE OF THE FASHION INDUSTRY

This year, VOICES will be delivered via a live broadcast adapted to the unique circumstances of the Covid-19 era and BoF Professional and BoF Professional Student members anywhere in the world can take part in this live global conversation as the industry looks ahead to 2021. If you are not a member, sign up today with our 30 day trial, including access to VOICES 2020.

Read more:
Learn from Leaders at Farfetch, Alibaba and, Rent the Runway at VOICES 2020 | BoF - The Business of Fashion

Four life-changing wellness retreats from around the world – Euronews

The new year is always a good time to 'reset' your life and implement new and improved health and fitness habits.

Maintaining new routines isnt easy, but here are four wellness retreats around the world that will help put the architecture in place that you need to live better.

Following the opening of Revivo in Bali in 2018, the brand will be launching a new wellness retreat in the Tarn region of France, in summer 2021.

Revivo Chteau de Fiac will take over a renovated castle on a three-hectare estate, and will feature 16 bedrooms, as well as a salt cave, a spa offering massages and hydrotherapy, bootcamp circuits, and the chance to eat freshly grown vegetables from the on-site garden.

Revivo is a proponent of teaching mind-body connectivity so always incorporates physical activity such as yoga with art classes and meditation, for example.

Also opening in spring/summer 2021, Qatars Zulal Wellness Resort will be the Middle Easts inaugural full-immersion wellness destination and the worlds first centre for traditional Arabic Islamic medicine.

Operated by wellness pioneer Chiva-Som, Zulal will have 120 rooms in a Family Wellness enclave, and 60 suites and villas in a separate zone for adults-only.

Just one hours drive away from Doha International airport, the extravagant hideaway will prescribe healing methods based on centuries of knowledge provided by Islamic medicinal historians and herbalists.

Situated in northern Goa, India, Kings Mansion will join Revivo and Zulal in making its debut in 2021.

Bringing together science and genomics with Ayurvedic medicine, the cutting-edge retreat will offer six wellbeing programmes, including areas such as:

Stays are a minimum of one week and both the Shodhana and Kshipra Shodhana detox programmes require a DNA test before arrival. These tests are to determine genetic pre-dispositions for certain health conditions, thereby allowing for highly personalised treatments.

Located on Lake Constance in southern Germany, Buchinger Wilhelmi is a hotel-clinic specialising in therapeutic fasting and integrative medicine.

In September it launched a new Immunity+ programme that is designed to boost wellbeing (with the specific aim of reducing the risk of getting Covid-19), and is bookable as a 110 add-on to its fasting packages.

After guests have been given a quick blood test on arrival to make sure they dont have Covid, they then get to relax in luxurious surroundings while embarking on a calorie-restricted regime (ten days costs 2,340 per person), which includes nurse checks, consultations with a doctor, daily activities, and a menu of freshly-made vegetable bouillon and pressed fruit juices.

Dr Francoise Wilhelmi de Toledo, scientific director at Buchinger Wilhelmi, explains, When you fast, all your digestive processes are in rest. Without needing the energy to digest, all stresses are diminished and you actually need less immunity.

"During this time, you change your microbiome. You stimulate the lungs, skin, kidneys, liver and the system itself triggers autophagy an extraordinary capacity of the body to eliminate damaged cellular structures. When you fast, you activate stem cells to rejuvenate immune cells.

Jenny Southan is editor and founder of travel trend forecasting agency Globetrender.

Read the original post:
Four life-changing wellness retreats from around the world - Euronews

Teresa Palmer selected as Top Holistic Health Practitioner of the Year by IAOTP – PRUnderground

Teresa Anne Palmer, Registered Nurse and Certified Nurse Practitioner, Holistic Healing and Integrative Stress Management Consultant, Certified Yoga and Meditation Therapist, Educator and Public Speaker for Wellness and Integrative Health Medicine was recently selected by the International Association of Top Professionals (IAOTP) for the Top Holistic Health Practitioner of the Year Award for 2021. Her exemplary role as a business professional displays influence, capability, and proficiency in her industry.

While inclusion with the International Association of Top Professionals is an honor in itself, only a few members in each discipline are chosen for this distinction. These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, longevity in the field, other affiliations, and contributions to their communities. All honorees are invited to attend the IAOTPs annual award gala at the end of this year for a night to honor their achievements. http://www.iaotp.com/award-gala

The President of IAOTP, Stephanie Cirami stated Choosing Teresa for this award was an easy decision for our panel to make. She is brilliant at what she does and her practices are unparalleled. She is humble, gracious and we are looking forward to honoring her at the gala this year. We know we will be seeing more amazing things from this incredible woman.

As an empowering force, Teresa is being recognized for having over 20 years of professional experience in the healthcare industry. Utilizing Meditation and Yoga, her main focus is on Stress Management. Teresa is highly skilled in the art of Integrative Health and Functional Medicine, meanwhile, she has demonstrated success and compassion as a Nurse Practitioner with a specialty in Cardiology for many years. Teresa believes in using Integrative Health Medicine to get to the root cause of a disease rather than just treating the symptoms.

Before focusing on a career in Integrative Health and the benefits of incorporating Meditation and Yoga, Teresa traveled to other countries, volunteering her time. While in Romania, she witnessed a monk fully recuperate from a heart attack because mentally he was determined to recover. His power of intention and positive mental attitude played a significant role in his ability to fully recover.

Completing her studies, Teresa is a Certified Adult Nurse Practitioner and a Certified Yoga Therapist with a special interest in medical conditions and expertise in stress recognition and reduction. She earned her Bachelor of Science and Master of Science in Nursing from Seton Hall University. Teresa is certified in Yoga Therapy through the American Yoga Academy and is certified in Functional Medicine and Complementary Care- Meditation. She also stands certified in Healthcare Innovation and Entrepreneurship.

Throughout her illustrious career, Teresa has received awards, accolades and has been recognized worldwide for her outstanding leadership and commitment to the profession. In 2021 she will be featured in TIP (Top Industry Professionals) Magazine. For 2020, she was chosen for the Empowered Woman of the Year Award. In 2019 she was selected as Top Nurse Practitioner of the Year by the International Association of Top Professionals (IAOTP) and was honored at their Annual Awards Gala in Las Vegas. Teresa has been featured in several editions of Whos Who in America, Whos Who in American Nursing, Whos Who of American Women, and Whos Who Among Human Services Professionals.

Aside from her successful career in healthcare, Teresa has been invited to speak on topics of stress, functional medicine, and the importance of yoga and meditation. Teresa is also an accomplished Author, her book Finding Sanctuary in the Pandemic Age, was released in September of 2020, focusing on achieving and maintaining health and wellbeing during challenging times.She has contributed numerous articles to peer-reviewed journals and other professional sources in her area of expertise, and has also been interviewed on CUTV News Radio.

Looking back, Teresa attributes her success to her perseverance, mentors she has had the honor of working alongside and remaining passionate by empowering individuals to heal themselves with their body, mind, and spirit. When not working, she enjoys writing, playing tennis, practicing yoga, and meditation. Teresa says she has been blessed, absolutely loves her work, and feels it is just the beginning. For the future, she hopes to continue to inspire and empower other individuals to live their healthiest and happiest lives.

Watch her video: https://www.youtube.com/watch?v=g_e_4V4XkYc

For more information on Teresa please visit: wellbeinggal.com

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the worlds finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and to help influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTPs experts have given thousands of top prestigious professionals around the world, the recognition and credibility that they deserve andhave helped in building their branding empires.IAOTP prides itself to bea one of a kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For More information on IAOTP please visit: http://www.iaotp.com

About IAOTP

The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the worlds finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and to help influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTPs experts have given thousands of top prestigious professionals around the world, the recognition and credibility that they deserve andhave helped in building their branding empires.IAOTP prides itself to bea one of a kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.

For More information on IAOTP please visit: http://www.iaotp.com

See the rest here:
Teresa Palmer selected as Top Holistic Health Practitioner of the Year by IAOTP - PRUnderground

Innosphere Ventures Fund Makes Seed Investment in Heads Up Health – North Forty News

Innosphere Ventures seed-stage venture capital fund has announced its investment in leading digital health analytics company Heads Up Health to compile further and organize complete medical histories.

Heads Up Health provides users and their healthcare providers the ability to see data they need to transform health outcomes through data from many sources such as wearables, genomics, labs, and electronic health records (EHR). Heads Up have also built a fully HIPPA compliant software-as-a-service (SaaS) platform that is cloud-based and has a web and mobile application that practitioners and patients use to track goal progress and improve their health outcomes, having been implemented by over 30,000 users in over 60 countries worldwide.

After we saw the Heads Up platform, we knew the company was perfectly positioned to lead the digital health analytics transformation and implement precision medicine with their world-class user interface and tools for patients and practitioners,said John Smith, Innosphere Ventures collaborator who led the investment into Heads Up with the funds General Partners and will join Heads Up Healths Board of Directors. The Heads Up platform will play a major part in new care delivery models, including personalized predictive and preventive solutions for an individuals health, John said.

Heads Up aim to utilize the investment capital from Innosphere Ventures to put an accelerated growth plan, which consists of adding enterprise-level capabilities to the product, increasing remote patient monitoring (RPM) billing features, and enhancing mobile app features, and growing the sales team. Heads Up also adds new customers across a range of healthcare verticals such as functional, integrative, concierge medicine, direct primary care, dieticians and nutritionists, and even wellness coaches.

We found the right partner in Innosphere Ventures; not only do they share our vision of the opportunity, but they bring an operators perspective and the network to help us lead the way, said Dave Korsunsky, founder and CEO of Heads Up. Its no secret that healthcare is undergoing massive technological and regulatory change, and our team is dedicated to building the best health platform that puts the power of data at your fingertips so that individuals and healthcare professionals can better optimize health, Dave said.

For more information regarding Heads Up Health, visit https://headsuphealth.com/ or for more information on The Innosphere Ventures Fund, visit:https://innosphereventures.org/or call 970-817-4791

Here is the original post:
Innosphere Ventures Fund Makes Seed Investment in Heads Up Health - North Forty News

The iceberg under the water: COVID mental health effects on nurses a major cause of concern – SILive.com

STATEN ISLAND, N.Y. Months after the coronavirus (COVID-19) first ravaged Staten Island, health care workers on the borough are once again staring down a flood of infections that is slowly filling the boroughs hospital beds only this time, the mental stresses wrought by the first wave are an equally-daunting problem.

Interviews with three nurses, a hospital executive and a social-work expert have shed a light on the damaging mental effects the coronavirus outbreak has had on health-care workers as the city moves toward a new stage of the pandemic.

Those effects, coupled with the culture of the nursing profession viewed by experts as not being conducive to discussing mental health have raised questions on the effectiveness of services available to those who are suffering and concerns about a seemingly-inevitable fallout of issues exacerbated by the virus.

I think every nurse is a different person and a different kind of nurse now, said an ICU nurse at Staten Island University Hospitals (SIUH) Princes Bay campus who requested anonymity.

I dont know if its more being numb, or being more prepared, she said. I feel like theres definitely some sort of PTSD involved.

Approaching the height of the pandemic in March, nurses who spoke to the Advance/SILive.com detailed a coronavirus nightmare that saw a startling number of hospitalizations and deaths in quick succession within the Islands two health care systems.

You would just get hit with all these patients dying at the same time, and there was no time to process any of it, said the ICU nurse. You just had to keep going. Put your feelings aside and just work.

Now, as nurses are beginning to process the grief they endured during the first wave of the outbreak, a new wave is emerging as hospitalizations have now reached levels not seen since the beginning of June.

A doctor walks into Richmond University Medical Center on Wednesday, Nov. 18, 2020. (Staten Island Advance/ Alexandra Salmieri) Alexandra SalmieriAlexandra Salmieri

TOLL ON PATIENTS BECOMING CLEARER

The mental health effects of the coronavirus on patients are becoming clearer as the pandemic progresses, and the outbreak has worsened addiction issues on the Island that experts feel are being largely ignored.

A nurse in Richmond University Medical Centers (RUMC) Psychiatric Emergency Room said she has seen an increase in drug-induced patients since the onset of the pandemic and has witnessed the disastrous effects of the coronavirus on the mental health of her patients.

You have your patients who are trying to use drugs to kill themselves, to forget things to kind of like forget whats going on, the nurse said, because they have nothing to do.

That increase of patients has also placed an undue burden on the nurses on the hospital floor, she added, explaining that it has become more important than ever to communicate with her colleagues about mental health.

We learn how to not internalize it, kind of work through our problems, she said. PTSD is a big thing for nurses in psych.

Her specific field psychiatry makes speaking about mental struggles more accepted than other nursing departments, she said, which has allowed her to leave her stress at work.

We work in such population that talking about mental health is not an embarrassment for us," she said.

That is not the case, however, across the nursing profession.

Dawn Cardello, an SIUH nurse of over 33 years and member of the New York State Nurses Associations executive committee, said she witnessed the stresses her nurses experienced first-hand.

Nurses, were traditionally flexible. We deal with a lot of things we bounce back and move forward, said Cardello, But we all know this was very different. It definitely has affected most nurses.

The onslaught of concerns over personal protective equipment that plagued staff early in the pandemic, coupled with the unfathomable number of deaths in quick succession, left even veteran nurses struggling.

I truly felt it, I felt the anxiety of my co-workers, an emotional Cardello said. A lot of nurses cry alone.

The emergency room at SIUH North in Ocean Breeze on Wednesday, Nov. 18, 2020. (Staten Island Advance/ Alexandra Salmieri) Alexandra SalmieriAlexandra Salmieri

ADDRESSING CONCERNS

Dr. Timothy Sullivan, the chair of Psychiatry and Behavioral Sciences at SIUH, called the stresses nurses faced during the spring extremely difficult and said Northwell Health which operates SIUH has established multiple efforts to address growing concerns surrounding the mental-health effects of the virus on staff.

They were on the front lines, they were in rooms with patients with active COVID, Sullivan said. Theyre having to talk to families about health care decisions, and so on, and all in an environment which we had not a lot of information.

Nurses were often given a difficult burden during the height of the pandemic on the borough, when over 500 residents were hospitalized between the Islands two health care systems, said Sullivan. Since then, a web of support was created by Northwell Health that includes an employee hotline and a program that specifically addresses stress and resilience.

Northwells Center for Traumatic Stress Resilience and Recovery, which previously focused primarily on working with veterans, began providing trainings to staff that would equip them with techniques such as psychological and stress first aid that are currently used by the military.

Sullivan said that transition was an integral one, as commonalities exist within the cultures of nurses and members of the armed forces.

Nurses often treat their co-workers like a team ... kind of like troops going into a battle, he said. While he recognized that approach as important, he also admitted that it makes it hard for people to acknowledge stress.

The program, implemented by Northwell and piloted at SIUH, is centered on both addressing the current mental state of staff while also cultivating an environment that makes mental health more accessible to speak about.

Stress first aid, for example, was developed in the military as a kind of prophylactic or preventative strategy that would help teams in military to be able to help one another to do self checks, said Sullivan, and to create a culture and a language that would make awareness of and comfort speaking about stress more normal.

There are roadblocks, however, to initiating programs like this. Buy-in among staff is necessary, and toppling decades-old expectations of avoiding mental health struggles within the profession is a tall task.

Staff members saw young people dying quickly, people dying alone, their families not able to be with them, and thats not stuff were used to. Sullivan said. So, that notion that it has affected people in a lasting way ... is understandable.

Weve got to find a way for people to talk about that with one another, he said.

The hospitals coronavirus hotline for staff, according to Sullivan, has quieted down since the height of the pandemic on Staten Island, and the unknown of the mental health struggles lying just under the surface is a considerable concern.

The difficult part is not knowing exactly whats out there, he said.

To overcome this, Sullivan said the health system is training leadership on the floors of the hospital to become coaches of the program in the effort to work within the already-established team mentality. Some members of SIUH were slated to complete the training by mid-November and were expected to enact the approach shortly afterward.

By integrating these techniques within the culture of the hospital, Sullivan said the health care system hopes it will help create constructive conversation.

So far, he said theres good buy in, but acknowledged, its really the iceberg under the water that we are unsure about.

And so thats why were pressing ahead with these efforts, Sullivan said.

Scenes from SIUH North in Ocean Breeze on Wednesday, Nov. 18, 2020. (Staten Island Advance/ Alexandra Salmieri) Alexandra SalmieriAlexandra Salmieri

EMOTIONAL FALLOUT STILL TO COME

Dr. Paul Archibald, assistant professor within the School of Social Work at the College of Staten Island, said the fallout of the first wave of the coronavirus is expected to leave an aftermath of a lot of mental health issues once the PTSD kicks in.

Archibald said the timing of the second wave of coronavirus hospitalizations is especially concerning, as It takes about six to eight months for the symptoms of PTSD to start showing itself.

Its like me watching somebody get murdered and six months later Im going through treatment and working through it, symptoms start to show up, and then I see another person get murdered, Archibald said. Thats whats happening.

Nurses experience a range of traumas in their everyday routine, according to Archibald, and the effects of those mental wounds can start to alter an individuals world view causing a nurse to undergo a series of drastic changes, including becoming potentially cynical or fearful.

Even those not fully traumatized by the COVID-19 pandemic can suffer vicarious trauma, which is the result of working in the vicinity of others who have suffered immensely. That, said Archibald, could lead health-care workers to experience secondary traumatic stress or compassion fatigue.

Im really concerned for the nurses and first responders and people who are working this COVID-19 pandemic, Archibald said. We have to make sure that mental health is a major part of this.

When contacted by the Advance/SILive.com, Alex Lutz, a RUMC spokesman, said the hospital does not specifically have a program for nursing staff to address mental health; however, the hospital has created a hotline that can refer anyone who is need of ongoing treatment.

Services are provided through RUMCs Center for Integrative Behavioral Medicine at South Avenue, said Lutz, adding that the hospital has offered services to employees, their families and friends.

We have dedicated experienced Behavioral Health clinicians who are available to staff needs at all times and we also make sure staff members get immediate appointments in our clinics once the contact is made, said Dr. Joel A. Idowu, chairman of RUMCs Department of Psychiatry & Behavioral Sciences. We do the same for referrals coming from our employee health department for our services.

Commenting on the hospitals hotline, the RUMC nurse said that staff within her department are unlikely to utilize the service.

She said that collaboration between nursing departments or specific programs crafted with nurses in mind would be more effective in addressing underlying issues that are facing staff as the Island enters a period of heightened hospitalizations.

And as the second wave is coming up, the nurse said the staff are working through the same difficulties they pushed through mentally about eight months ago. Yes, were more prepared, but at the same time whos working through it?

Archibald stressed that having programs in place was an important first step, but acknowledged that just having the resources does not mean people are going to buy in to it.

You cant just have these services ..., he said. If I wasnt calling all along, Im not going to start now.

Follow this link:
The iceberg under the water: COVID mental health effects on nurses a major cause of concern - SILive.com

Microglia, the brain’s trash collector cells, may play larger role in brain health, may reveal clues to disease treatments – National Institute on…

Microglia are a minority among brain cells, but a new study in mice is adding to the evidence that these trash collector cells may have a mightier role in brain health and disease, and could provide clues to new treatment targets for neurodegenerative diseases such as Alzheimers. Funded in part by NIA and published in Nature, this latest research suggests there is a microglia-driven negative feedback mechanism that is modifying how neurons act.

Neurons, which make up about 50% of brain cells, have long been viewed as the drivers of brain processes, such as thoughts and behavior. Meanwhile microglia, representing only about 10% of brain cells, have been seen as the clean-up crew. For their job as the brains immune cells, microglia remove dying neurons, prune synapses, and generally support the survival of neurons.

A research team at the Icahn School of Medicine at Mount Sinai performed a series of experiments in mice, including the removal of microglia from specific brain regions. Led by Anne Schaefer, M.D., Ph.D., Professor of Neuroscience and Psychiatry, and a 2012 NIH Directors New Innovator Award Recipient, researchers compared neuronal responses to different insults and controls. When the microglia were removed, at first the neurons were fine, but then went haywire, showing a seizure response to insults.

The findings show a circuit between neurons and microglia that involve the molecule adenosine triphosphate (ATP). When neurons are active, they release ATP, which attracts microglia. The microglia in turn break down ATP into forms of adenosine, which suppress synaptic transmission and neuron activity. Without microglia, or when microglia dont respond to ATP, the seizure response kicks in with excessive neuronal activity.

The researchers also looked at this circuit in an Alzheimers disease mouse model and saw the same seizure response. They hypothesize that this type of microglia-induced neuromodulation may go awry in neurodegenerative diseases, including Alzheimers and Huntingtons, and contribute to increases in neuron excitability and behavior changes that are associated with those disorders. Targeting the microglia system could potentially be a therapeutic protecting the brain from abnormal activation seen in neurodegenerative diseases.

As a next step, Dr. Schaefer and colleagues are starting to investigate the epigenetic mechanisms of microglia activation during aging and its contributions to neurodegenerative diseases. NIA recently awarded the Icahn School of Medicine at Mount Sinai a $2.99 million grant (number RF1AG068558) toward this effort targeting microglial epigenetic regulators specific to inflammation.

This research was funded in part by NIA grants R01AG045040, U01AG058635, and T32AG049688.

These activities relate to NIHs AD+ADRD Research Implementation Milestone 2.A, "Create new research programs that use data-driven, systems-based approaches to integrate the study of fundamental biology of aging with neurobiology of aging and research on neurodegeneration, AD and AD-related dementias to better understand the mechanism(s) of vulnerability and resilience in AD across all levels of biologic complexity (from cellular to population level) and to gain a deeper understanding of the complex biology and integrative physiology of healthy and pathologic brain aging." They also relate to Milestone 2.B, "Establish new research programs that employ data-driven, systems-based approaches to understand the interaction between peripheral systems (in particular: immune, metabolic, microbiome) and the brain and the impact of this interaction on brain aging and neurodegeneration. These efforts should integrate human and animal model research and characterize the extent to which molecular (epigenomic, transcriptomic and metabolomic) variation identified in peripheral tissues can be used as a proxy for inter-individual variation in the trajectories of brain aging, AD and AD-related dementias."

Reference: Badimon A, et al. Negative feedback control of neuronal activity by microglia. Nature. 2020;586(7829):417-423. doi: 10.1038/s41586-020-2777-8.

Here is the original post:
Microglia, the brain's trash collector cells, may play larger role in brain health, may reveal clues to disease treatments - National Institute on...

Society of Vascular and Interventional Neurology Releases Study on Paradigm Shifts in Medical Care During COVID-19 Pandemic – Southernminn.com

MINNEAPOLIS, Nov. 19, 2020 /PRNewswire/ -- The Society of Vascular and Interventional Neurology(SVIN)colleagues andDr. James Siegleridentify that it should come as no surprise that the COVID-19 pandemic and its many "waves" has led to significant paradigm shifts in medical care--from triage all the way to treatment, and SVIN and Dr. Sieglerare releasing a study on Paradigm Shifts in Medical Care During COVID-19Pandemic. Many reports have indicated that patients are avoiding healthcare institutions to prevent contact with COVID-19 patients and healthcare professionals.Falling rates have been observed across a range of acute and critical conditions including myocardial infarction, stroke, and various cancers.The long-term consequences of healthcare avoidance remain unknown but will become clear in the coming months and years.

Using a novel lens to explore these indirect consequences of the COVID-19 pandemic,Dr.Sieglerand colleagues from the Society of Vascular andInterventionalNeurology undertook amulticenterobservational study to evaluate the timeline of critical care that is provided to patients with acute ischemic stroke. These investigators pooled prospectively maintained data from 14 Comprehensive Stroke Centers (CSCs) in nine U.S. states between January 2019 and July 2020.Together, these nine states accounted for nearly half of all COVID-19 cases in the U.S. and more than one-third of all COVID-19-associatedmortalities.(If any indirect effect of the pandemic were to influence the care of stroke patients, it would involve these high-risk geographical regions.) The objective of this investigation was to determine if patients were receiving standard-of-carereperfusiontherapies (e.g., intravenousthrombolysisand/orthrombectomy) with the same expediency during the COVID-19 period as they were in the months prior. Using the AHA Target: Stroke campaign goal of a 60-minute door-to-needle time for intravenousthrombolysisas a primary outcome, the authors found that patients admitted to these hospitals during the COVID-19 pandemic were at a 45% lower odds of being treated in that 60-minute time window (adjusted OR 0.55, 95%CI 0.35-0.85).

The investigators were also able to track the times from patient arrival to firstneuroimagingtothrombolysisbolus. It appears that the principal mediator of the delay inthrombolysiswas the delay in time from head imaging to bolus (median delay of sevenminutes across all sites).Despite the increased need for personal protective equipment, contact precautions, and other barriers between patients and providers, there appeared to be no delay in time from arrival to firstneuroimaging.Furthermore, the delay in care appeared to persist throughout the months of June and July as the second wave of the pandemic spread across the southeastern and western United States.While the overall delay tothrombolysiswas minimal (median delay of only fourminutes), this delay was observed inCSCs, which are known to have faster throughput and treatment times when compared to other healthcare institutions.It is possible that this delay may be magnified in community hospitals, and these findings warrant exploration in non-CSC institutions.

Although there was a mild but significant delay in door-to-needle times during the COVID-19 pandemic, there appeared to be no significant delay in door-to-groin puncture times for patients who underwentendovascularrecanalizationduring COVID-19. This may reflect the careful planning and anticipation of COVID-19 patient care by leaders within the Society of Vascular andInterventionalNeurology, as their consensus guidelines had been published early during the pandemic.

Altogether, these findings suggest large scale gaps in acute medical care for a common neurological problem that affects almost 1 million Americans perannum. It is important for healthcare institutions to appraise their local paradigms in acute stroke care to determine if similar gaps exist, and what steps they can take to reduce delays in care during a global crisis.

About SVIN

The Society of Vascular andInterventionalNeurologyachieves the highest level ofpatient care through collaboration in scientific research and education.The Society provides opportunities to connect leaders in the field and provides a platform for dialogue and creation of practicestandards.Our mission is to advance vascular andinterventionalneurologyto improve clinical outcomes of stroke and cerebrovascular disorders.

For further information about SVIN, visitwww.svin.orgor find us on Facebook, Twitter, orLinkedIn.Media Contact: Jennifer Potter-Vig, PhD |info@svin.org|952-646-2045

Related Images

dr-jim-siegler.jpgDr. Jim SieglerSpeaking on behalf of the Society of Vascular and Interventional Neurology (SVIN) COVID-19 Registry & Task Force at the SVIN Annual Meeting on Thursday, November 19, 2020.

Related Links

SVIN Annual Meeting

See original here:
Society of Vascular and Interventional Neurology Releases Study on Paradigm Shifts in Medical Care During COVID-19 Pandemic - Southernminn.com

Sustained Benefit of Ocrelizumab Treatment for Primary Progressive MS – Neurology Advisor

Long-term follow-up from the phase 3 ORATORIO extension study (ClinicalTrials.gov Identifier: NCT01194570) provided evidence of a consistent, long-term benefit of early and continuous ocrelizumab treatment on disease progression in primary progressive multiple sclerosis (PPMS), according to study results published in the Lancet Neurology.

Data from the phase 3 ORATORIO trial supported the safety and efficacy of ocrelizumab for patients with PPMS. The objective of this follow-up study was to evaluate the long-term safety and efficacy of maintaining or switching to ocrelizumab therapy in the open-label extension phase of the trial.

ORATORIO was a multi-center, double-blind, phase 3 trial of 732 patients with PPMS. Patients were aged 18-55 years and randomly assigned to receive intravenous ocrelizumab or placebo, every 24 weeks for at least 120 weeks. After the double-blind phase, the participants entered an extended controlled period, followed by an open-label extension phase, during which they continued ocrelizumab or switched from placebo to ocrelizumab.

Time to onset of disability progression was confirmed at 24 weeks months by using 4 measures: increase in Expanded Disability Status Scale score; 20% or more increase in time to complete the 9-Hole Peg Test; 20% or more increase in time to perform the Timed 25-Foot Walk; and composite progression, defined as the first confirmed occurrence of any of these three individual measures.

Of 732 participants, 544 (74%) completed the double-blind period to week 144; 517 of these patients and 10 additional ones (total, 527 [72%]) entered the open-label extension phase. Of the 527 patients, 451 (86%), were ongoing in the open-label extension.

Over a period of 6.5 study years, there was a consistent and sustained treatment-associated benefit in multiple measures of disability progression. The proportion of patients with worsening disability measures was lower in those who initiated ocrelizumab early, compared with those who switched from receiving placebo: Expanded Disability Status Scale (51.7% vs 64.8%, respectively; P =.0018); 9-Hole Peg Test (30.6% vs 43.1%, respectively; P =.0035); Timed 25-Foot Walk (63.2% vs 70.7%, respectively; P =.058), and composite progression (73.2% vs 83.3%, respectively; P =.0023).

Percent changes in T2 lesion volume (0.447% vs 13.002%, respectively; P <.0001) and T1 hypointense lesion volume (36.676% vs 60.925%, respectively; P =.0008) from baseline to the end of the study were lower for patients who were on ocrelizumab from the double-blind phase of the study, compared with those who switched from placebo.

The rate of adverse events and serious adverse events over the entire period in the all-ocrelizumab exposure population were 238.09 (95% CI, 232.71-243.57) per 100 patient-years and 12.63 (95% CI, 11.41-13.94) per 100-patient years, respectively. The most common serious adverse events were serious infections with a rate of 4.13 (95% CI, 3.45-4.91) per 100 patient-years. No new safety signals emerged.

The study had several limitations, including the lack of a control group, open-label treatment, and potential survivor bias.

Although this study shows the benefit of earlier intervention with ocrelizumab in primary progressive disease, progression remains an important unmet need in multiple sclerosis, concluded the study researchers.

Reference

Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. Published online October 29, 2020). doi:10.1016/S1474-4422(20)30342-2

Follow this link:
Sustained Benefit of Ocrelizumab Treatment for Primary Progressive MS - Neurology Advisor

NeurOptics’ Neurological Pupil index and Automated Pupillometry Included in New American Heart Association Guidelines for CPR and Emergency…

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--NeurOptics Neurological Pupil index (NPi) and automated pupillometry are now included in the updated 2020 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) as an objective measurement supporting brain injury prognosis in patients following cardiac arrest.

The AHA guidelines outline the latest global resuscitation science and treatment recommendations derived from the 2020 International Consensus on CPR and ECC and are considered the gold standard of clinical recommendations in the practice of resuscitation science. The guidelines were last updated in 2015 and reflect alignment with the International Liaison Committee on Resuscitation and associated member councils.

Automated infrared pupillometry is an objective assessment of the pupillary light reflex that is measured using NeurOptics NPi-200 Pupillometer. The NPi-200 Pupillometer provides an objective measurement of pupil size and reactivity and calculates the Neurological Pupil index (NPi). NPi values range from 0 to 4.9, with scores under 3 considered abnormal. The NeurOptics NPi-200 Pupillometer eliminates the variability and subjectivity inherent in manual pupillary evaluation, providing more accurate, reliable, and objective pupil size and reactivity measurement for this vital component of neurological examinations in patients with the potential for brain injury across a broad spectrum of conditions, including patients who have suffered cardiac arrest.

According to the new AHA guidelines, most deaths attributable to post-cardiac arrest brain injury are due to active withdrawal of life-sustaining treatment based on a predicted poor neurological outcome.1 Automated assessment of pupillary reactivity, measured by the NPi, provides a standard, reproducible measurement of pupil size and reactivity to help support the prognosis of poor neurological outcome in patients who remain comatose 72 hours after cardiac arrest.1-3

The expansion of the AHA guidelines to include automated pupillometry with the Neurological Pupil index (NPi) to monitor patients who have suffered a cardiac arrest reflects the growing adoption and validation of automated pupillometry for use in patients with brain injury, said William Worthen, President and CEO of NeurOptics. The NPi scale removes subjectivity from the neurological evaluation, providing clinicians with more accurate, objective and reliable pupil data that can be trended over time, and allows earlier detection of changes for timelier patient treatment. We are pleased to see automated pupillometry included in these new guidelines.

The 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care were published in the journal Circulation, and can be found here.

About NeurOptics

Headquartered in Laguna Hills, Calif., NeurOptics is the leader in the science of pupillometry. Driven by a passion to help clinicians improve patient outcomes, NeurOptics develops and markets innovative technology for use in critical care medicine, neurology, neurosurgery, emergency medicine, and research. The NeurOptics NPi-200 Pupillometer has been included in more than 50 clinical studies, adopted in over 440 trauma and stroke centers in the United States, and is represented in more than 26 countries worldwide. For more information, visit http://www.NeurOptics.com. Follow NeurOptics on Facebook, LinkedIn and Twitter @NeurOpticsInc.

References

Go here to read the rest:
NeurOptics' Neurological Pupil index and Automated Pupillometry Included in New American Heart Association Guidelines for CPR and Emergency...

What is Trending in Neurovascular Devices Interventional Neurology Market? What are the Strategies to Boost Business in Near Years? – The Daily…

Latest Neurovascular Devices Interventional Neurology Market Research Report Cover Covid-19 Impact:

The Neurovascular Devices Interventional Neurology report provides an independent information about the Neurovascular Devices Interventional Neurology industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Neurovascular Devices Interventional Neurology Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Neurovascular Devices Interventional Neurology Market: Products in the Neurovascular Devices Interventional Neurology classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Stryker Corporation , Medtronic PLC , Johnson & Johnson , Terumo Corporation , Penumbra, Inc. , Boston Scientific Corporation , Microport Scientific Corporation , Merit Medical Systems, Inc. , W.L. Gore & Associates, Inc. , Abbott Laboratories

Have Any Query Or Specific Requirement?Ask Our Industry Experts!

Neurovascular Devices Interventional Neurology Market Report Covers the Following Segments:

Segmentation by Type:Aneurysm Coiling & Embolization DevicesEmbolic CoilsBare Detachable CoilsCoated Detachable CoilsFlow Diversion DevicesLiquid Embolic AgentsCerebral Balloon Angioplasty and Stenting SystemsCarotid Artery StentsEmbolic Protection SystemsDistal Filter DevicesBalloon Occlusion DevicesSupport DevicesMicrocathetersMicroguidewiresNeurothrombectomy DevicesClot Retrieval DevicesSuction and Aspiration DevicesSnaresSegmentation by Application:Ischemic StrokesCerebral AneurysmsArteriovenous Malformation and FistulasOther Disease pathology

Market Size Segmentation by Region & Countries (Customizable):

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Neurovascular Devices Interventional Neurology Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Neurovascular Devices Interventional Neurology Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Neurovascular Devices Interventional Neurology Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Neurovascular Devices Interventional Neurology Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Neurovascular Devices Interventional Neurology Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Neurovascular Devices Interventional Neurology Market.

Market Forecast:Here, the report offers a complete forecast of the global Neurovascular Devices Interventional Neurology Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

For detailed information https://brandessenceresearch.biz/Medical-Devices-and-Consumables/Neurovascular-Devices-Interventional-Neurology-Market-Register-Strong-Growth-to-2025/Summary

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

http://www.marketwatch.com/press-release/new-zealand-milking-systems-market-share-industry-size-opportunities-analysis-growth-factors-and-forecast-2025-2020-11-17

https://www.marketwatch.com/press-release/fmcg-market-2020-size-share-global-industry-growth-business-statistics-top-leaders-competitive-landscape-forecast-to-2025-2020-11-12?tesla=y

https://www.marketwatch.com/press-release/cellulose-ester-market-size-global-industry-analysis-and-opportunity-assessment-2020-2025-2020-11-13?tesla=y

https://www.marketwatch.com/press-release/telemedicine-market-size-to-surpass-usd-14832-billion-by-2025-analysis-types-trends-share-industry-insights-trends-and-forecast-upto-2025-2020-08-12?tesla=y

https://www.marketwatch.com/press-release/over-2084-cagr-viral-vector-manufacturing-market-will-bypass-124-billion-by-2025-2020-11-12?tesla=y

Excerpt from:
What is Trending in Neurovascular Devices Interventional Neurology Market? What are the Strategies to Boost Business in Near Years? - The Daily...